Charlene Mantia

Also affiliated with Dana-Farber Cancer Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214”.

Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009495

N/A

0.615DataRank · unranked

19 citations

Opeyemi A. Jegede, Elizabeth R. Plimack, Thomas Powles, Robert J. Motzer, Nizar M. Tannir +13 more

Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-003743

N/A

0.542DataRank · unranked

36 citations

Charlene Mantia, Lillian Werner, Ahmad A. Tarhini, James Larkin, F. Stephen Hodi +10 more

FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma

BJUI Compass(2021)10.1002/bco2.125

N/A

0DataRank · unranked

15 citations

Talal El Zarif, Rohit Jain, William Paul Skelton, Dory Freeman, Catherine Curran +8 more